BioMarin reports Q1 EPS $1.13, consensus 95c

Reports Q1 revenue $745.1M, consensus $738.66M. The company said, “During the first quarter, we saw continued high demand for our innovative medicines resulting in strong revenue growth and profitability,” said Alexander Hardy, President and Chief Executive Officer of BioMarin (BMRN). “Products in our pipeline also advanced according to plan. In April, we shared positive top-line results from the Phase 3 PALYNZIQ study for the treatment of adolescents with phenylketonuria between the ages of 12 and 17. Also in April, we were pleased to conclude enrollment in the pivotal study in hypochondroplasia with VOXZOGO, keeping us on track to launch in 2027, should data be supportive.”